Introduction & Objectives: While A1c is a strong predictor of conversion from prediabetes to type 2 diabetes, it is unclear whether A1c values within the prediabetes range confer the same risk of conversion to type 2 diabetes within different adult age groups.

Methods: Using linked population-based administrative health databases, we investigated the progression from prediabetes to diabetes among adults (≥20 years) with laboratory criteria for prediabetes living in Ontario, Canada between 2012-2022. New diabetes cases were captured using a well-validated administrative data algorithm. Competing risk and Cox proportional hazards models were used to assess the association between A1c increments (~0.2%) within the prediabetes range (5.70-6.49%, vs <5.7%) and diabetes incidence in different decades.

Results: Among 3,022,169 individuals with prediabetes, 139,450 (4.6%; mean age 54.1 ± 15.8 yrs) progressed to diabetes over a mean follow up of 4.78 years. The cumulative incidence of diabetes was greatest among those with baseline A1C levels of 6.30-6.49% in both younger (20-29 yrs: 34.5%) and older adults (≥70 yrs: 19.2%). Increased A1c conferred a far greater relative risk of progression to diabetes in adults aged 20-29 and 30-39 (A1c 6.30-6.49%: HR 51.7, 95% CI 45.0-59.3 and HR 41.3, 38.8-44.0, respectively). Relative conversion rates were more modest in adults aged ≥70 years across all A1c categories (A1c 6.30-6.49%: HR 9.7, 9.3-10.1).

Conclusion: Baseline A1c was a stronger predictor of conversion from prediabetes to diabetes among younger adults, suggesting that diabetes prevention efforts should consider baseline A1C and age to reduce future risk of progression.

Disclosure

G.S. Fazli: None. L. Lipscombe: Other Relationship; Novo Nordisk Canada Inc. D. Thiruchelvam: None. C. Kenaszchuk: None. B.R. Shah: None. C. Ke: Advisory Panel; Sanofi. Speaker's Bureau; AstraZeneca. F.M. Ali: None. L. Rosella: None. G.L. Booth: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.